Trop

Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target

OSS, the Netherlands, June 27, 2007-Organon, the humanhealthcare business unit of Akzo Nobel, announced today that twoout of three Phase III clinical trials with corifollitropin alfa(Org 36286), a new long-acting fertility hormone, have reachedtheir randomization target. Corifollitropin alfa is a new recombinant fertility hormone. It isthe first of a new class of gonadotropi...

Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis

RESEARCH TRIANGLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINESSWIRE)--Jun 26, 2007 - Tranzyme Pharma, a leading biopharmaceuticalcompany developing small molecule drugs for the treatment ofgastrointestinal and metabolic diseases, today announced positiveresults for its novel ghrelin agonist, TZP-101, in acceleratinggastric emptying in diabetic patients with gastroparesis. The datafrom a pi...

Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics

Trophos Describes Identification, Characterization and BroadNeuroprotective Properties of TRO19622 in Journal of Pharmacologyand Experimental Therapeutics Neurodegenerative Disease Specialists Publish Details of a NovelDrug Candidate for ALS That Targets Mitochondrial Proteins MARSEILLE, June 19th, 2007 - Trophos SA, a biopharmaceuticalcompany specializing in the discovery an...

Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedical's Electroporation DNA Delivery Technology

SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today that thecompany's partner, Vical Incorporated, presented positive interimsafety and tolerability data on 18 subjects from an ongoing Phase Iclinical trial...

Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today the companydelivered multiple presentations on preclinical study results andnew device innovations relating to its electroporation-mediated DNAdelivery te...

Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association

* Ozarelix Effective in Improving Symptoms and Urine Flow, WithLong Lasting Effect in Phase 2 Study IRVINE, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- SpectrumPharmaceuticals, Inc., today announced Phase 2 safety and efficacydata for ozarelix, the Company's drug candidate for the treatmentof benign prostatic hypertrophy (BPH), at the American UrologyAssociation Annual Meeting held at...

Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues

MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that in a recently completed animalstudy, a DNA vaccine formulated with the company's patentedVaxfectin(TM) adjuvant and delivered by needle-free injectionyielded significantly higher antibody responses than anunformulated DNA vaccine delivered by needle and syringe. In aseparate animal study, electro...

New Position Statement from The North American Menopause Society Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in Postmenopausal Women

CLEVELAND--(BUSINESS WIRE)--May 10, 2007 - An evaluation of thesafety and effectiveness of local vaginal estrogen therapy for thetreatment of vaginal atrophy, a frequent complaint ofpostmenopausal women, has just been released by The North AmericanMenopause Society (NAMS). Entitled "The role of local vaginalestrogen for treatment of vaginal atrophy in postmenopausal women:2007 position stat...

PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy

Data Presented at 59th American Academy of Neurology Annual Meeting BOSTON and SOUTH PLAINFIELD, N.J., May 04, 2007 /PRNewswire/ --PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focusedon the discovery and development of small-molecule drugs targetingpost-transcriptional control processes, today announced positiveinterim data from a Phase 2 clinical trial of PTC124 in patientsw...

Insmed Announces Promising Results From IPLEX Phase II Myotonic Muscular Dystrophy Clinical Study

RICHMOND, Va.--(BUSINESS WIRE)--May 3, 2007 - Insmed Inc.(Nasdaq:INSM) today announced positive results from a Phase IIinvestigator-sponsored study of the company's drug, IPLEX(TM), inpatients with myotonic muscular dystrophy (DM1). Preliminary results of the clinical study, being conducted atthe University of Rochester School of Medicine and Dentistry,showed that six months of treatment...

Researchers Find Surprising Pattern of Influenza Spread in South America and Tropics

BETHESDA, Md., March 20, 2007--Researchers studying influenzatransmission patterns in the Southern Hemisphere and in tropicalareas, specifically Brazil, uncovered the unexpected finding thateach season influenza travels from low populated regions near theequator to the more populated centers. Their work, funded by theFogarty International Center (NIH), part of the National Institutesof H...